Thursday, April 19, 2012

Daiichi Sankyo buys out 100% equity in Xinshengyuan, with a view to leverage Ranbaxy and its own product line

Daiichi Sankyo today announced acquisition of 100% stake in Xinshengyua, susbsidiary of the Shanghai Xinshengyuan Pharmaceutical (Group) Co. The acquisition will enable import and marketing of Ranbaxy and its own line of drugs into China. In absence of new product launches, Daiichi is leveraging its hybrid model to the full to fuel growth in the company.